David A. Siegel Galectin Therapeutics Inc Transaction History

Two Sigma Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.24 - $2.87 $35,616 - $45,633	-15,900 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.53 - $3.64 $10,373 - $14,924	4,100 Added 34.75%	15,900 $42,000
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $19,588 - $37,170	11,800 New	11,800 $36,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $68.3M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.